Synageva information

Synageva BioPharma Corp. was a publicly listed biopharmaceutical company (Nasdaq: GEVA) headquartered in Lexington, Massachusetts dedicated to discovering...

hypophosphatasia, for as much as $1.08 billion. In June 2015, Alexion acquired Synageva, a maker of rare disease treatments, in an $8.4 billion stock-and-cash...

into Alexion Antibody Technologies Inc) Enobia Pharma Corp (Acq 2011) Synageva BioPharma (Acq 2015) Wilson Therapeutics (Acq 2018) Syntimmune (Acq 2018)...

hypophosphatasia, a rare metabolic disorder. In 2015 Alexion estimated that Synageva, its specialty drug for lysosomal acid lipase deficiency, a fatal genetic...

with lysosomal acid lipase (LAL) deficiency. Sebelipase was developed by Synageva that became part of Alexion Pharmaceuticals in 2015. For its production...

Retrieved 1 November 2015. Chelsey Dulaney (May 6, 2015). "Alexion to Buy Synageva for $8.4 Billion". The Wall Street Journal. Retrieved May 7, 2015. "Valeant...